Development of a Rhinovirus Inoculum Using a Reverse Genetics Approach.

Area of Science:

• Virology
• Immunology
• Respiratory Medicine

Background:

• Experimental inoculation is crucial for common cold and asthma research.
• Traditional methods for producing rhinovirus (RV) inocula require extensive donor screening to prevent pathogen contamination.
• A novel method for RV inoculum production is needed to streamline research processes.

Purpose of the Study:

• To produce a Rhinovirus type A, strain 16 (RV-A16) inoculum using reverse genetics.
• To determine the optimal dose of RV-A16 inoculum for inducing moderate cold symptoms in volunteers.
• To establish a stable and safe source of RV for laboratory research.

Main Methods:

• The consensus sequence of RV-A16 was cloned, and infectious virus was generated via reverse genetics.
• Safety testing was performed before inoculating volunteers.
• Volunteers received either RV-A16 or a placebo, with cold severity assessed using Jackson cold scores and viral shedding measured via RNA detection.

Main Results:

• Reverse genetics successfully produced infectious RV-A16, neutralized by specific antisera.
• A dose of 1000 median tissue culture infectious dose (TCID50) reliably induced moderate cold symptoms.
• The induced symptoms were comparable to those from conventional RV inocula.

Conclusions:

• Reverse genetics provides a viable method for producing RV-A16 inocula for experimental use.
• This recombinant approach ensures a stable virus supply and eliminates the risk of extraneous pathogen contamination from nasal secretions.
• The method facilitates the study of common cold and asthma by providing a safe and standardized viral challenge agent.